Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, and Hippo pathway signaling and YAP/TAZ.
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.
PT2.11.01 Predictors of Response to PD-(L)1 Blockade in Patients With Oncogene-Driver Negative NSCLC Without History of Tobacco Use
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.
Supplementary Figure S5 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Table S3 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S22 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S1 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Table S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S21 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S16 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S20 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S14 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Table S2 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Table S5 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S10 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S4 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S15 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S11 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S17 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S12 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Gene mutant dosage determines prognosis and metastatic tropism in 60,000 clinical cancer samples
Data from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S19 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S13 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S3 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Figure S9 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Table S1 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Supplementary Table S4 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy